Advertisements



Sorrento Therapeutics expands clinical development of resiniferatoxin

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 15th, 2019

Sorrento Therapeutics to present clinical trial data for resiniferatoxin

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 27th, 2020

Abeona Therapeutics appoints Seshadri as Head of Research & Clinical Development

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 25th, 2021

Panbela Therapeutics names Garry Weems as VP of clinical development

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 15th, 2021

Pliant Therapeutics appoints Gregory Cosgrove as VP, clinical development, IPF

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 4th, 2021

Ovid Therapeutics announces pipeline, clinical development updates

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 7th, 2020

3 Keros Analysts On Why Biopharma Is A Compelling Investment Opportunity

Keros Therapeutics Inc (NASDAQ: KROS), a clinical-stage biopharma focused on the development of treatments for rare hematologic and musculoskeletal disorders, Latest Ratings fo.....»»

Category: blogSource: benzingaMay 4th, 2020

VistaGen Therapeutics to expand clinical development of PH94B

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 28th, 2020

Plus Therapeutics appoints Gregory Stein as head of clinical development

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 1st, 2020

Proteostasis Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Corporate Update

BOSTON, March 10, 2020 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) throu.....»»

Category: earningsSource: benzingaMar 10th, 2020

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results

SAN DIEGO, March 04, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives, reported financial results for th.....»»

Category: earningsSource: benzingaMar 4th, 2020

ProQR Therapeutics expects to advance QR-504a to clinical development in 2020

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallFeb 26th, 2020

Stemline Therapeutics Announces Preliminary 2019 Net Revenues for ELZONRIS® (tagraxofusp) and Highlights Commercial and Clinical Growth Drivers

NEW YORK, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, today announced prelim.....»»

Category: earningsSource: benzingaJan 13th, 2020

Revive Therapeutics to focus on clinical development of CBD for AIH treatment

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 6th, 2020

CymaBay Halts Study On Lead Clinical Program, Stock Crashes

CymaBay Therapeutics Inc (NASDAQ: CBAY) shares are losing more than 75% of their value Monday after the company said it's halting the development of its lead drug, seladelpar. 0 read more.....»»

Category: blogSource: benzingaNov 25th, 2019

Artelo Biosciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update

LA JOLLA, Calif., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate the endocannabinoid system, today reported financial and .....»»

Category: earningsSource: benzingaNov 25th, 2019

Crinetics Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrin.....»»

Category: earningsSource: benzingaAug 13th, 2019

Sorrento Therapeutics says Phase 1b resiniferatoxin trial met day 84 goals

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 19th, 2019

Sorrento Therapeutics to accelerate human IND filing of resiniferatoxin

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 10th, 2019

miRagen Therapeutics to Report First Quarter 2019 Financial Results and Host a Conference Call on May 8th

BOULDER, Colo., April 25, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of R.....»»

Category: earningsSource: benzingaApr 25th, 2019

Sangamo Therapeutics, Inc. (SGMO) Sangamo Clinical Development Update Conference Call (Transcript)

Sangamo Therapeutics, Inc. (SGMO) Sangamo Clinical Development Update Conference Call (Transcript).....»»

Category: topSource: seekingalphaApr 6th, 2019